Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma.

Authors

• Maria R Cavallo
• Jacob C Yo
• Kayla C Gallant
• Camille J Cunanan
• Amirali Amirfallah
• Marzieh Daniali
• Alyssa B Sanders
• Andrew E Aplin
• Edmund A Pribitkin
• Edward J Hartsough

Publication/Presentation Date

4-15-2024

Abstract

Papillary thyroid carcinoma (PTC) is the most frequent form of thyroid cancer. PTC commonly presents with mutations of the serine/threonine kinase BRAF (BRAF

Volume

10

Issue

1

First Page

175

Last Page

175

ISSN

2058-7716

Published In/Presented At

Cavallo, M. R., Yo, J. C., Gallant, K. C., Cunanan, C. J., Amirfallah, A., Daniali, M., Sanders, A. B., Aplin, A. E., Pribitkin, E. A., & Hartsough, E. J. (2024). Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma. Cell death discovery, 10(1), 175. https://doi.org/10.1038/s41420-024-01945-0

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

38622136

Department(s)

Administration and Leadership

Document Type

Article